Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Diagnosing Large Vestibular Aqueduct: Radiological Review of High-Resolution CT Versus High-Resolution Volumetric MRI
Deep, Nicholas L. , Carlson, Matthew L. , Weindling, Steven M. , Barrs, David M., Driscoll, Colin L. W., Lohse, Christine M. , Lane, John I. , Hoxworth, Joseph M.

Mayo Clinic

Otology & Neurotology | June 9, 2017 | Volume: 38 | Issue: 7 | Pages: 948-955

10.1097/mao.0000000000001482 | PMID 28604576 Get It

Objectives: To compare the diagnostic yield of high-resolution volumetric T2-weighted MRI (HRT2-MRI) with high-resolution computed tomography (HRCT) for diagnosis of large vestibular aqueduct (LVA). Study Design: Three board-certified neuroradiologists performed an independent, blinded radiological review for diagnosing LVA with 2:1 age-matched controls on patients with both HRCT and HRT2-MRI imaging. Setting: Tertiary referral center. Patients: All patients between 2002 and 2016 with hearing loss who underwent both HRCT and HRT2-MRI and were diagnosed with LVA on either modality. Main Outcome Measures: Concordance rate for LVA between HRCT and HRT2-MRI. Results: Concordance rate for HRCT and HRT2-MRI for diagnosing LVA was 88% (124/141) when assessing both the midpoint and external aperture diameters. Fifteen ears had LVA on computed tomography (CT), but not on magnetic resonance imaging (MRI); in comparison, two ears had LVA on MRI, but not on CT (p = 0.002). Excellent inter-rater reliability among the three radiologists was demonstrated. Conclusion: Historically, HRCT has been the imaging modality of choice for diagnosing LVA. Although a higher concordance rate of HRT2-MRI was found compared with previous studies utilizing earlier MRI technology, HRCT still detected a larger number of patients with clinically significant hearing loss compared with MRI. Given the high concordance rate and efficacy of both modalities in diagnosing LVA, the ultimate decision of which modality to choose may depend on other patient-specific and clinical factors.
Pilot Feasibility Study of a Digital Storytelling Intervention for Immigrant and Refugee Adults With Diabetes
Wieland, Mark L. , Njeru, Jane W. , Hanza, Marcelo M., Boehm, Deborah H., Yawn, Barbara P. , Clark, Matthew M. , Weis, Jennifer A., Goodson, Miriam, Capetillo, Maria D. Porraz, Hared, Abdullah, Hasley, Rachel, Guzman-Corrales, Laura , Sandler, Rachel, Hernandez, Valentina, Novotny, Paul J. , Sloan, Jeff A. , Sia, Irene G. , Patten, Christi A. , Porraz Capetillo, Maria D, Singh, Davinder , Osman, Ahmed , Wieland, Mark L , Sia, Irene G

Mayo Clinic

The Diabetes Educator | June 8, 2017 | Volume: 43 | Issue: 4 | Pages: 349-359

10.1177/0145721717713317 | PMID 28592205 Get It

Purpose The purpose of this pilot feasibility project was to examine the potential effectiveness of a digital storytelling intervention designed through a community-based participatory research (CBPR) approach for immigrants and refugees with type 2 diabetes mellitus (T2DM). Methods The intervention was a 12-minute culturally and linguistically tailored video consisting of an introduction, 4 stories, and a concluding educational message. A structured interview was used to assess the intervention for acceptability, interest level, and usefulness among 25 participants with T2DM (15 Latino, 10 Somali) across 5 primary care clinical sites. After watching the video, participants rated their confidence and motivation about managing T2DM as a result of the intervention. Baseline A1C and follow-up values (up to 6 months) were abstracted from medical records. Results All participants reported that the intervention got their attention, was interesting, and was useful; 96% reported that they were more confident about managing their T2DM than before they watched the video, and 92% reported that the video motivated them to change a specific behavior related to T2DM self-management. The mean baseline A1C level for the intervention participants was 9.3% (78 mmol/mol). The change from baseline to first follow-up A1C level was −0.8% (−10 mmol/mol) ( P < .05). Conclusions Implementation of a digital storytelling intervention for T2DM among immigrant populations in primary care settings is feasible and resulted in self-rated improvement in psychosocial constructs that are associated with healthy T2DM self-management behaviors, and there was some evidence of improvement in glycemic control. A large-scale efficacy trial of the intervention is warranted.
PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL NON‐HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T‐CELL CONSORTIUM
Lunning, M., Mehta–Shah, Neha , Moskowitz, Alison J. , Beaven, Anne , Haverkos, Bradley M. , Lechowicz, MaryJo, Oki, Yasuhiro , Ansell, Stephen M. , Lunning, Matthew A. , Horwitz, Steven M. , Advani, Ranjana H. , Zain, Jasmine

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 411-412

10.1002/hon.2439_190 Get It

HOST GENETIC VARIATION IN THE TNF AND NF‐ĸB PATHWAYS AND PROGNOSIS IN MANTLE CELL LYMPHOMA: AN ANALYSIS OF 2 STUDIES
Wang, Y., Wang, S.S., Inwards, David J. , Rothman, Nathaniel , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Witzig, Thomas E. , Cozen, Wendy , Morton, Lindsay M. , Chanock, Stephen Jacob , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 151-152

10.1002/hon.2438_4 Get It

PROGNOSTIC FACTORS AND IMPACT OF ETOPOSIDE IN ADULTS WITH SYSTEMIC ALK‐POSITIVE ANAPLASTIC LARGE‐CELL LYMPHOMA: A POOLED ANALYSIS OF SIX STUDIES
Nguyen, Dinh-Phong , Schmitz, Norbert , Lamant, Laurence , Weisenburger, Dennis D. , Ziepert, Marita , Bast, M., Tilly, H., Jaïs, Jean Philippe, Sibon, David , Suzuki, Ritsuro , Feldman, Andrew L. , Gressin, Rémy , Nakamura, Shôji , Maurer, Matthew J. , Armitage, Jamés O. , Vose, Julie M. , Savage, Kerry J.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 240-240

10.1002/hon.2438_103 Get It

GB VIRUS‐C (GBV‐C) INFECTION AND RISK OF LYMPHOMA: A CASE‐CONTROL STUDY FROM NORTH AMERICA
Allmer, Cristine, Xiang, Jinhua , Klinzman, Donna, Feldman, Anya, Nowakowski, Grzegorz S. , Liebow, Mark , Larson, Matthew , Call, Timothy G. , Famà, Angelo , Link, Brian K. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R. , Stapleton, Jack T.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 55-56

10.1002/hon.2437_40 Get It

CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS
Ghesquières, Hervé , Nicolas‐Virelizier, Emmanuelle , Thompson, C., Traverse‐Glehen, Alexandra , Allmer, Cristine, Ansell, Steven M., Sarkozy, Clémentine , Link, Brian K. , Maurer, Matthew J. , Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Bachy, Emmanuel , Cerhan, James R. , Salles, Gilles

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 34-35

10.1002/hon.2437_15 Get It

Increasing Body Mass Index Is Associated with Worse Outcomes After Shoulder Arthroplasty
Wagner, Eric R. , Schleck, Cathy D. , Harmsen, William S. , Cofield, Robert H. , Sperling, John W. , Elhassan, Bassem T. , Houdek, Matthew T. , Sánchez‐Sotelo, Joaquín , Wagner, Eric R

Mayo Clinic

Journal of Bone and Joint Surgery | June 7, 2017 | Volume: 99 | Issue: 11 | Pages: 929-937

10.2106/jbjs.15.00255 | PMID 28590378 Get It

Background: Although obesity is associated with increased complication rates after lower-extremity arthroplasty, there is a relative paucity of studies examining the effect of body mass index (BMI) on shoulder arthroplasty. The purpose of this investigation was to evaluate the effect of BMI on implant survival and the rate of complications after shoulder arthroplasty. Methods: Using an institutional total joint registry, 4,567 consecutive shoulder arthroplasty cases from 1970 to 2013 were studied. The mean BMI was 29.7 kg/m 2 (range, 14 to 66 kg/m 2 ), with 1,622 patients (36%) with a BMI of 30 to 40 kg/m 2 and 297 patients (7%) with a BMI of >40 kg/m 2 . There were 2,493 female patients (55%). BMI was dichotomized after examination of the smoothing spline curve. The associations of factors and complications were assessed using Cox proportional hazard regression analysis. Results: Increasing BMI was associated with an increased risk of a revision surgical procedure, reoperation, revision for mechanical failure, and superficial infection, and it was negatively associated with risk of a periprosthetic fracture. The risk of a revision surgical procedure increased in a linear fashion with increasing BMI (hazard ratio [HR], 1.05, or a 5% increased risk per 1 unit of BMI; p = 0.03). Increased BMI was also associated with an increased risk of revision for mechanical failure (HR, 1.05; p = 0.004). In a multivariate model, the association of BMI and risk of a revision for any reason, revision for mechanical failure, and reoperation maintained significance (p ≤ 0.02). The most marked association between increasing BMI and any complication in shoulder arthroplasty was its association with superficial wound infection (HR, 1.09; p = 0.03). Conclusions: Increasing BMI is strongly associated with increased rates of revision surgical procedures and postoperative complications after shoulder arthroplasty. It is important to consider these findings when counseling patients, estimating risks, and estimating complication risks in policy decisions. Level of Evidence: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Abstract MIP-056: CONSTITUTIVELY ACTIVE ESTROGEN RECEPTOR–ALPHA LIGAND BINDING DOMAIN (ERA–LBD) MUTATIONS IN OVARIAN CARCINOMA
Elvin, Julia A. , Gay, L., Colon-Otero, G., Jorgensen, Matthew S., Havrilesky, L., Zajchowski, Deborah A., Shawver, Laura K. , Aithal, Sramila, Ross, Jeff , Markman, Maurie , Elvin, Julia A , Valea, Fidel A. , Gaillard, Stéphanie

Mayo Clinic

Clinical Cancer Research | June 6, 2017 | Volume: 23 | Issue: 11_Supplement | Pages: MIP-056-MIP-056

10.1158/1557-3265.ovcasymp16-mip-056 Get It

Abstract OBJECTIVES: Mutations in ESR1 that are acquired following treatment with aromatase inhibitors commonly underlie resistance to endocrine therapy in breast cancer. ERa-LBD mutations, especially at ESR1 Y537 and D538, confer constitutive activity and partial resistance to selective estrogen receptor modulators (SERMs), such as tamoxifen, and degraders (SERDs) such as fulvestrant in transcription assays. Some ovarian tumors also respond to anti-hormone therapy, and a subset which initially respond subsequently become resistant. The mechanisms of resistance to hormone therapy in ovarian cancer have not been previously described. Comprehensive genomic profiling (CGP) of ovarian tumors was used to analyze ESR1 and correlate responsiveness to aromatase inhibitors in a subset of these patients. METHODS: DNA was extracted from tumor specimens and sequenced using hybridization-capture (FoundationOne) targeting up to 315 genes, plus select introns frequently rearranged in cancer. Demographic and clinicopathologic data will be presented for a subset of patients whose tumors harbor ERa-LBD mutations associated with activation and resistance.. RESULTS: CGP of 3,641 ovarian and peritoneal carcinomas revealed 31 (0.9%) samples with amplification of ESR1 and 16 (0.4%) samples with acquired or de novo mutations affecting the ERa-LBD: Y537S (10), Y537N (1), D638G (4), and S341L (1). Within the 16 samples, ovarian serous carcinoma (10), ovarian endometrioid adenocarcinoma (3), ovarian epithelial carcinoma NOS (2), and peritoneal serous carcinoma (1) were represented. In cases of acquired mutations following prior hormone therapy, there was evidence of clinical benefit to SERM/SERDs. CaseAgeDiseaseESR1 MutationPrior HRTAcquiredSERM/SERD (*post mut if acquired)Clinical Benefit SERM/SERD159Ov serousY537SYYNN/A258Papillary serousY537NNNYY344Endometrioid ov adenoY537SNNYY445HG ov serousD538GNUYU564Endometrioid ov adenoY537SYUNU646LG ov serousY537SYUYU739Papillary serousY537SYUNN/A827LG ov serousY537SYYYY CONCLUSIONS: Acquired activating mutations in ESR1, previously described in breast cancer, can occur in ovarian serous carcinomas and endometrioid carcinomas initially responsive to hormone therapy and suggest a similar mechanism for acquired aromatase inhibitor resistance. However, ERa mutations can occur in gynecologic malignancies even in the absence of prior endocrine therapy. Tumors harboring these mutations may remain responsive to SERM/SERDs. Citation Format: J. A. Elvin, L. Gay, G. Colon-Otero, M. Jorgensen, L. Havrilesky, D. Zajchowski, L Shawver, F. A. Valea, S Aithal, J. S. Ross, M. Markman, S. Gaillard. CONSTITUTIVELY ACTIVE ESTROGEN RECEPTOR–ALPHA LIGAND BINDING DOMAIN (ERA–LBD) MUTATIONS IN OVARIAN CARCINOMA [abstract]. In: Proceedings of the 11th Biennial Ovarian Cancer Research Symposium; Sep 12-13, 2016; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(11 Suppl):Abstract nr MIP-056.